Loading clinical trials...
Loading clinical trials...
An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary Disease
Conditions
Interventions
Bisantrene Dihydrochloride (high dose)
Bisantrene Dihydrochloride (low dose)
+2 more
Locations
1
Australia
Calvary Mater
Newcastle, New South Wales, Australia
Start Date
July 29, 2022
Primary Completion Date
August 31, 2023
Completion Date
August 31, 2023
Last Updated
October 3, 2023
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
Race Oncology Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions